KR20210018898A - 조직 손상 및 집중 치료 후 증후군의 치료 및 예방을 위한 할로겐 화합물의 용도 - Google Patents

조직 손상 및 집중 치료 후 증후군의 치료 및 예방을 위한 할로겐 화합물의 용도 Download PDF

Info

Publication number
KR20210018898A
KR20210018898A KR1020217000098A KR20217000098A KR20210018898A KR 20210018898 A KR20210018898 A KR 20210018898A KR 1020217000098 A KR1020217000098 A KR 1020217000098A KR 20217000098 A KR20217000098 A KR 20217000098A KR 20210018898 A KR20210018898 A KR 20210018898A
Authority
KR
South Korea
Prior art keywords
iodide
subject
injury
certain embodiments
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020217000098A
Other languages
English (en)
Korean (ko)
Inventor
스티븐 에이. 힐
마크 비. 로스
존 더블유. 랭스턴
마이클 엘. 모리슨
아키코 이와타
마이클 앤드류 인스코
Original Assignee
패러데이 파마슈티컬스, 인코포레이티드
프레드 헛친슨 켄서 리서치 센터
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 패러데이 파마슈티컬스, 인코포레이티드, 프레드 헛친슨 켄서 리서치 센터 filed Critical 패러데이 파마슈티컬스, 인코포레이티드
Publication of KR20210018898A publication Critical patent/KR20210018898A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/18—Iodine; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020217000098A 2018-06-08 2019-06-07 조직 손상 및 집중 치료 후 증후군의 치료 및 예방을 위한 할로겐 화합물의 용도 Ceased KR20210018898A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862682574P 2018-06-08 2018-06-08
US62/682,574 2018-06-08
US201862730927P 2018-09-13 2018-09-13
US201862730945P 2018-09-13 2018-09-13
US62/730,945 2018-09-13
US62/730,927 2018-09-13
PCT/US2019/036154 WO2019237065A1 (en) 2018-06-08 2019-06-07 Use of halogen compounds for the treatment and prevention of tissue injury and post-intensive care syndrome

Publications (1)

Publication Number Publication Date
KR20210018898A true KR20210018898A (ko) 2021-02-18

Family

ID=68770655

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217000098A Ceased KR20210018898A (ko) 2018-06-08 2019-06-07 조직 손상 및 집중 치료 후 증후군의 치료 및 예방을 위한 할로겐 화합물의 용도

Country Status (10)

Country Link
US (1) US20210252047A1 (https=)
EP (1) EP3801565A4 (https=)
JP (1) JP2021527130A (https=)
KR (1) KR20210018898A (https=)
CN (1) CN112469422A (https=)
AU (1) AU2019282820A1 (https=)
CA (1) CA3102792A1 (https=)
IL (1) IL279221A (https=)
MX (1) MX2020013306A (https=)
WO (1) WO2019237065A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX386702B (es) 2014-02-10 2025-03-19 Fred Hutchinson Cancer Center Tratamiento con halogeno de ataque cardiaco y lesion isquemica.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6248335B1 (en) * 1997-10-29 2001-06-19 Symbollon Corporation Stabilized oral pharmaceutical composition containing iodide and iodate and method
CZ295765B6 (cs) * 1998-07-29 2005-10-12 Apa - Praha, S.R.O. Léčebný přípravek s virucidním účinkem
GB0525504D0 (en) * 2005-12-14 2006-01-25 Bristol Myers Squibb Co Antimicrobial composition
MX386702B (es) * 2014-02-10 2025-03-19 Fred Hutchinson Cancer Center Tratamiento con halogeno de ataque cardiaco y lesion isquemica.

Also Published As

Publication number Publication date
AU2019282820A1 (en) 2021-01-21
CA3102792A1 (en) 2019-12-12
EP3801565A4 (en) 2022-04-06
JP2021527130A (ja) 2021-10-11
EP3801565A1 (en) 2021-04-14
CN112469422A (zh) 2021-03-09
US20210252047A1 (en) 2021-08-19
MX2020013306A (es) 2021-05-12
WO2019237065A1 (en) 2019-12-12
IL279221A (en) 2021-01-31

Similar Documents

Publication Publication Date Title
US12016880B2 (en) Halogen treatment of heart attack and ischemic injury
US12458593B2 (en) Suspensions and diluents for metronidazole and baclofen
Hall et al. Sequential treatment with quinine and mefloquine or quinine and pyrimethamine-sulfadoxine for falciparum malaria.
KR20210018898A (ko) 조직 손상 및 집중 치료 후 증후군의 치료 및 예방을 위한 할로겐 화합물의 용도
WO2021257806A1 (en) Iodide for treatment of nonthyroidal illness syndrome
KR20150021509A (ko) 칼코게나이드를 포함하는 조성물 및 관련 방법
JP6856813B1 (ja) 亜鉛点滴静注用製剤
Braun et al. Meningoencephalitis in a child complicated by myocarditis, quadriparesis and respiratory failure
HK1231000B (en) Treatment of heart attack and ischemic injury with sodium iodide
HK1231000A1 (en) Treatment of heart attack and ischemic injury with sodium iodide
CN101234096A (zh) 匹多莫德胶囊制剂及其制备方法

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20210104

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20220428

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20250317

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20250520

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D